Published in Pituitary on January 01, 2009
Dual-Port 2D and 3D Endoscopy: Expanding the Limits of the Endonasal Approaches to Midline Skull Base Lesions with Lateral Extension. J Neurol Surg B Skull Base (2014) 0.97
Combined simultaneous transcranial and transsphenoidal resection of large-to-giant pituitary adenomas. Acta Neurochir (Wien) (2011) 0.83
An endoscopic modification of the simultaneous 'above and below' approach to large pituitary adenomas. Pituitary (2012) 0.81
Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol (2015) 0.78
The Pterional Port in Dual-Port Endoscopy: A 2D and 3D Cadaveric Study. J Neurol Surg B Skull Base (2014) 0.75
Anterior and posterior suprasellar extensions of a symmetrical trilobed nonfunctional giant pituitary adenoma in the sagittal plane: a case report and review of literature. Radiol Case Rep (2016) 0.75
Giant Chondroma of the Saddle Area: Case Report and Literature Review. Neuroophthalmology (2013) 0.75
Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients. Childs Nerv Syst (2014) 0.75
Forced subarachnoid air in transsphenoidal excision of pituitary tumors (pumping technique) J Neurosurg (1989) 2.10
The history and evolution of transsphenoidal surgery. J Neurosurg (2001) 1.80
Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg (1986) 1.53
Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery (2007) 1.52
Transsphenoidal hypophysectomy. J Neurosurg (1971) 1.36
Surgical treatment of giant pituitary adenomas. J Neurol Neurosurg Psychiatry (1979) 1.33
Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control. J Neurosurg (1965) 1.30
A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg (1984) 1.21
Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol (1976) 1.19
Loss of vision after transsphenoidal surgery. Neurosurgery (1990) 1.19
Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg (2000) 1.13
Management of nonfunctioning pituitary adenomas with suprasellar extensions by transsphenoidal microsurgery. Surg Neurol (1999) 1.12
Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary (2008) 1.11
Combined transsphenoidal and pterional craniotomy approach to giant pituitary tumors. Surg Neurol (2002) 1.10
Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery (2001) 1.02
The transsphenoidal removal of nonfunctioning pituitary adenomas with suprasellar extensions: the open sella method and intentionally staged operation. Neurosurgery (1995) 0.98
Surgical approaches to suprasellar and parasellar tumors. Neurosurg Clin N Am (2003) 0.94
[The recurrence of pituitary adenoma after transfrontal, transphenoidal or 2-stage combined operation]. Wien Med Wochenschr (1970) 0.93
Transsphenoidal-transtuberculum sellae approach for supradiaphragmatic tumours: technical note. Acta Neurochir (Wien) (1998) 0.93
Management of large pituitary adenomas by transsphenoidal surgery. Surg Neurol (1988) 0.91
Key personalities in the development and popularization of the transsphenoidal approach to pituitary tumors: an historical overview. Neurosurg Clin N Am (2003) 0.88
Combined supra-infrasellar approach for large pituitary tumors. Neurosurgery (1984) 0.88
Surgical approaches to pituitary tumors. Neurosurg Clin N Am (2003) 0.88
The role of transcranial surgery in the management of pituitary adenoma. Acta Neurochir Suppl (1996) 0.84
Management of huge pituitary adenomas. Acta Neurochir Suppl (1996) 0.82
Transsphenoidal extracapsular approach to pituitary tumors. J Neurosurg (1986) 0.81
Results of surgical management of 319 pituitary adenomas. Acta Neurochir (Wien) (1987) 0.78
Role of transsphenoidal operation in the management of pituitary adenomas with suprasellar extension. Acta Neurochir (Wien) (1989) 0.78
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery (2008) 2.33
Beneficial use of a new hand-held CO2 laser fiber in resection of a calcified and vascular intraventricular tumor. World Neurosurg (2011) 2.18
Intracranial infectious aneurysms: a comprehensive review. Neurosurg Rev (2009) 2.11
The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg (2013) 2.01
Simulation in neurosurgery: a review of computer-based simulation environments and their surgical applications. Neurosurgery (2010) 1.86
Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia (2006) 1.83
Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther (2007) 1.80
Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One (2011) 1.77
Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery (2002) 1.57
Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985) (2004) 1.57
The surgical management of chronic subdural hematoma. Neurosurg Rev (2011) 1.54
Epithelioid pituicytoma. World Neurosurg (2011) 1.39
Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther (2010) 1.39
Astrocytic regulation of human monocytic/microglial activation. J Immunol (2008) 1.32
Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol (2004) 1.30
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
Magnetic resonance imaging characteristics of glioblastoma multiforme: implications for understanding glioma ontogeny. Neurosurgery (2010) 1.19
Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage. Neurosurgery (2010) 1.16
Metastases to the pineal gland. Neurology (2006) 1.15
Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am (2010) 1.13
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res (2006) 1.12
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) (2009) 1.11
Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary (2008) 1.11
The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol (2009) 1.11
Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol (2009) 1.11
From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin (2009) 1.10
Meningiomas of the velum interpositum: surgical considerations. Neurosurg Focus (2003) 1.07
Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab (2008) 1.07
MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clin Endocrinol (Oxf) (2010) 1.05
A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol (2010) 1.02
Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol (2008) 1.01
Approaches to anterior and anterolateral foramen magnum lesions: A critical review. J Craniovertebr Junction Spine (2010) 1.00
Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res (2009) 1.00
Convection-enhanced delivery in the treatment of malignant glioma. Neurol Res (2006) 1.00
Tumor-associated macrophages in glioma: friend or foe? J Oncol (2013) 1.00
Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol (2010) 0.99
Technological advances in the management of unruptured intracranial aneurysms fail to improve outcome in New York state. Stroke (2011) 0.99
Surgical management of craniopharyngiomas. J Neurooncol (2009) 0.98
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
Motor deficits correlate with resting state motor network connectivity in patients with brain tumours. Brain (2012) 0.97
Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol (2002) 0.95
Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery (2006) 0.95
The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol (2009) 0.94
Incidence, cost, and mortality associated with hospital-acquired conditions after resection of cranial neoplasms. Neurosurgery (2014) 0.94
An improved test of neurological dysfunction following transient focal cerebral ischemia in rats. J Neurosci Methods (2006) 0.94
Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery (2007) 0.93
Renal dysfunction as an independent predictor of outcome after aneurysmal subarachnoid hemorrhage: a single-center cohort study. Stroke (2009) 0.93
Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res (2010) 0.92
Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab (2005) 0.92
Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary (2003) 0.91
Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. J Neurooncol (2013) 0.91
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol (2011) 0.90
Pre-operative intracranial meningioma embolization. Expert Rev Neurother (2011) 0.90
MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet (2012) 0.90
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma. Neurol Res (2012) 0.90
Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab (2012) 0.89
Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab (2002) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol (2007) 0.89
Medulloblasoma: challenges for effective immunotherapy. J Neurooncol (2011) 0.88
Evoked potential monitoring identifies possible neurological injury during positioning for craniotomy. Anesth Analg (2009) 0.88
Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol (2009) 0.88
MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol (2013) 0.88
Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res (2011) 0.88
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol (2013) 0.87
Complement inhibition as a proposed neuroprotective strategy following cardiac arrest. Mediators Inflamm (2010) 0.87
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol Cancer Ther (2006) 0.86
A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. J Clin Neurosci (2012) 0.86
Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue. J Neurooncol (2014) 0.86
Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr (2012) 0.86
Endotoxin stimulates leptin in the human and nonhuman primate. J Clin Endocrinol Metab (2003) 0.86
Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci (2012) 0.85
Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab (2014) 0.84
Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro Oncol (2012) 0.84
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery (2014) 0.84
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol (2006) 0.84
Surgical approaches to the pineal region. Neurosurg Clin N Am (2011) 0.83
Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery. J Clin Endocrinol Metab (2008) 0.83
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res (2003) 0.83
Surgical approaches to posterior third ventricular tumors. Neurosurg Clin N Am (2003) 0.83
Tuberculosis of the pituitary and sellar region. Pituitary (2002) 0.83
Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2. Bioorg Med Chem Lett (2012) 0.82
The survival impact of postoperative infection in patients with glioblastoma multiforme. Neurosurgery (2009) 0.82
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab (2004) 0.81
CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther (2002) 0.81
Neurosurgical oncology: advances in operative technologies and adjuncts. J Neurooncol (2014) 0.81
Retroviral delivery of platelet-derived growth factor to spinal cord progenitor cells drives the formation of intramedullary gliomas. Neurosurgery (2012) 0.80
Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv (2013) 0.80
Harvey Cushing, neurosurgical pioneer. Curr Surg (2005) 0.80
PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. Hum Mol Genet (2012) 0.80
Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experience. J Neurooncol (2015) 0.79
Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system. Neurocrit Care (2007) 0.79
Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab (2010) 0.79